In this context, and consistent with our previous work demonstrating the implication of the iNOS/NO system in colitis-associated cancer and colorectal cancer, particularly in immune escape, tissue damage, and therapeutic response (28, 29), we sought to further investigate the NOS2/ARG1 axis by stratifying CRC patients according to high or low expression levels. This evidence concerns the gene ARG1 and colorectal carcinoma.